![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca and Bristol-Myers Squibb Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S
AstraZeneca and Bristol-Myers Squibb Resubmit Dapagliflozin New Drug Application for the Treatment of Type 2 Diabetes in the U.S
July 25, 2013
AstraZeneca and Bristol-Myers Squibb have resubmitted a New Drug Application for dapagliflozin for type 2 diabetes. The new submission includes new studies and more long-term data.
AstraZeneca
AstraZeneca
Upcoming Events
-
21Oct